DISEASE RECURRENCE AND PROGRESSION IN UNTREATED PATHOLOGIC STAGE T3 PROSTATE CANCER: SELECTING THE PATIENT FOR ADJUVANT THERAPY

Abstract

No AccessJournal of UrologyClinical Urology: Original Articles1 Oct 1997DISEASE RECURRENCE AND PROGRESSION IN UNTREATED PATHOLOGIC STAGE T3 PROSTATE CANCER: SELECTING THE PATIENT FOR ADJUVANT THERAPY Bruce A. Lowe and Stephen F. Lieberman Bruce A. LoweBruce A. Lowe and Stephen F. LiebermanStephen F. Lieberman View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)64240-XAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Optimal management of pathologic T3 prostate cancer is poorly defined. We conducted a prospective study of untreated pT3 patients to improve understanding of the natural history of this disease and to identify clinical parameters useful in patient selection for adjuvant therapy. Materials and Methods: Of 583 consecutive patients with clinical stage T1 to 2 disease managed by total prostatectomy, 206 had pT3 disease. Excluding patients requesting immediate adjuvant treatment or neoadjuvant therapy, 156 subjects were eligible for the study, including 34 with pT3a, 80 pT3b, 22 pT3c, and 20 pT3N + disease. Patients were followed for prostate-specific antigen (PSA) recurrence of greater than 0.2 ng./ml. and biopsy proved local or distant tumor progression demonstrated by imaging studies. Results: After a median of 45 months, PSA recurrence was seen in 29.4% of pT3a (10/34), 30% of pT3b (24/80), 27.3% of pT3c (6/22), and 80% of pT3N+ (16/20 cases). Local or distant progression was seen in 2.9% of pT3a (1), 6.2% of pT3b (5), 9.1% of pT3c (2), and 55% of pT3N+ (11 cases). Recurrence and progression correlated with the number of surgical margins involved by tumor, pathological Gleason score and baseline pre-prostatectomy PSA levels. PSA recurrence was seen in 20.8% (10/48) patients with 1 surgical margin involved, 40.9% (9/22) with 2 margins involved and 50% (5/10) with 3 or more margins involved. PSA recurrence was 20.3% (14/69) with Gleason scores of less than 7, 33.9% (19/56) with a score of 7 and 74.2% (23/31) with scores of greater than 7. Pre-prostatectomy PSA levels less than 10 ng./ml. were associated with a PSA recurrence of 17.3% (14/81) and 45.4% (25/55), with levels greater than 10 ng./ml. Selecting patients for high or low risk based upon the results of these parameters allowed accurate prediction of PSA recurrence; 8.5% (4/47) for low risk patients and 44.8% (30/67) for high risk. Tumor progression was seen in no low risk patient and in 9% (6) with high risk. The difference between the 2 risk groups was highly significant (p <0.0001). Conclusions: The majority of patients with pT3 prostate cancer will not experience recurrent disease for many years if ever. Immediate use of adjuvant treatment should be reserved for those patients with a high risk of recurrent disease. References 1 : Positive surgical margins at radical prostatectomy: importance of the apical dissection.. J. Urol.1990; 143: 1166. Abstract, Google Scholar 2 : Postsurgical management of the patient undergoing radical prostatectomy.. Brit. J. Urol., suppl.1992; 70: 43. Google Scholar 3 : Perineal versus retropubic prostatectomy for T1, T2 prostate cancer. Brit. J. Urol.1994; 74: 626. Google Scholar 4 : Positive margins after radical prostatectomy: correlation with local recurrence and distant progression.. Brit. J. Urol.1993; 72: 489. Google Scholar 5 : Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome.. Urology1993; 43: 828. Google Scholar 6 : Prostate specific antigen related to clinical status 1 to 14 years after radical prostatectomy.. Brit. J. Urol.1991; 67: 626. Google Scholar 7 : Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins.. Urology1996; 47: 225. Google Scholar 8 : Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten year update.. Int. J. Rad. Oncol. Biol. Phys.1995; 33: 37. Google Scholar 9 : Adjuvant irradiation after prostatectomy for carcinoma of the prostate with positive surgical margins.. Cancer1994; 73: 384. Google Scholar 10 : Postoperative radiation therapy after radical prostatectomy for prostate carcinoma.. Cancer1992; 70: 1960. Google Scholar 11 : Extended experience with radical prostatectomy for clinical state T3 prostate cancer: outcome and contemporary morbidity.. J. Urol.1995; 154: 1447. Abstract, Google Scholar 12 : Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results.. J. Urol.1990; 144: 1180. Abstract, Google Scholar 13 : Impact of radical prostatectomy in the management of clinically localized disease.. J. Urol.1994; 152: 1826. part 2. Abstract, Google Scholar 14 : The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy.. J. Urol.1993; 149: 1024. Abstract, Google Scholar 15 : Patient evaluation of prostate specific antigen that becomes elevated following radical prostatectomy or radiation therapy.. Urol. Clin. N. Amer.1994; 21: 677. Google Scholar 16 : The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy.. J. Urol.1994; 152: 1821. part 2. Abstract, Google Scholar 17 : Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup.. J. Urol.1993; 150: 135. Abstract, Google Scholar 18 : Five year follow-up after radical prostatectomy for localized prostate cancer-a study of the impact of different tumor variables on progression.. Scand. J. Urol. Nephrol.1994; 28: 391. Google Scholar 19 : A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol.1995; 154: 131. Google Scholar From the Oregon Health Sciences University and Kaiser-Permanente, Sunnyside, Portland, Oregon.© 1997 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byPisansky T, Thompson I, Valicenti R, D'Amico A and Selvarajah S (2019) Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019Journal of Urology, VOL. 202, NO. 3, (533-538), Online publication date: 1-Sep-2019.Thompson I, Valicenti R, Albertsen P, Davis B, Goldenberg S, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf J and Faraday M (2013) Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO GuidelineJournal of Urology, VOL. 190, NO. 2, (441-449), Online publication date: 1-Aug-2013.Jayachandran J, Bañez L, Levy D, Aronson W, Terris M, Presti J, Amling C, Kane C and Freedland S (2008) Risk Stratification for Biochemical Recurrence in Men With Positive Surgical Margins or Extracapsular Disease After Radical Prostatectomy: Results From the SEARCH DatabaseJournal of Urology, VOL. 179, NO. 5, (1791-1796), Online publication date: 1-May-2008.SOFER M, HAMILTON-NELSON K, CIVANTOS F and SOLOWAY M (2018) Positive Surgical Margins After Radical Retropubic Prostatectomy: The Influence of Site and Number on ProgressionJournal of Urology, VOL. 167, NO. 6, (2453-2456), Online publication date: 1-Jun-2002.BLUTE M, BERGSTRALH E, IOCCA A, SCHERER B and ZINCKE H (2018) USE OF GLEASON SCORE, PROSTATE SPECIFIC ANTIGEN, SEMINAL VESICLE AND MARGIN STATUS TO PREDICT BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMYJournal of Urology, VOL. 165, NO. 1, (119-125), Online publication date: 1-Jan-2001.GROSSFELD G, TIGRANI V, NUDELL D, ROACH M, WEINBERG V, PRESTI J, SMALL E and CARROLL P (2018) MANAGEMENT OF A POSITIVE SURGICAL MARGIN AFTER RADICAL PROSTATECTOMY: DECISION ANALYSISJournal of Urology, VOL. 164, NO. 1, (93-100), Online publication date: 1-Jul-2000.GROSSFELD G, CHANG J, BROERING J, MILLER D, YU J, FLANDERS S, HENNING J, STIER D and CARROLL P (2018) IMPACT OF POSITIVE SURGICAL MARGINS ON PROSTATE CANCER RECURRENCE AND THE USE OF SECONDARY CANCER TREATMENT: DATA FROM THE CAPSURE DATABASEJournal of Urology, VOL. 163, NO. 4, (1171-1177), Online publication date: 1-Apr-2000.Blute M and Zincke H (2018) RE: PATHOLOGICAL FEATURES AND PROGNOSTIC SIGNIFICANCE OF PROSTATE CANCER IN THE APICAL SECTION DETERMINED BY WHOLE MOUNT HISTOLOGYJournal of Urology, VOL. 162, NO. 4, (1391-1392), Online publication date: 1-Oct-1999.D'AMICO A, WHITTINGTON R, MALKOWICZ S, FONDURULIA J, CHEN M, TOMASZEWSKI J and WEIN A (2018) THE COMBINATION OF PREOPERATIVE PROSTATE SPECIFIC ANTIGEN AND POSTOPERATIVE PATHOLOGICAL FINDINGS TO PREDICT PROSTATE SPECIFIC ANTIGEN OUTCOME IN CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, VOL. 160, NO. 6 Part 1, (2096-2101), Online publication date: 1-Dec-1998. Volume 158Issue 4October 1997Page: 1452-1456 Advertisement Copyright & Permissions© 1997 by American Urological Association, Inc.MetricsAuthor Information Bruce A. Lowe More articles by this author Stephen F. Lieberman More articles by this author Expand All Advertisement PDF downloadLoading ...